NEOTEC programme selects Sequentia Biotech’s project Artepharming

In May 2017 our research line in biopharming has been selected for financing by the CDTI (Centre for Industrial Technological Development) from MINECO in the framework of the budget line NEOTEC. The NEOTEC programme aims to support the creation and consolidation of technology-based companies.

Biopharming or Plant Molecular Pharming combines biotechnology and agriculture to produce valuable medicinal products in plants with a reduced cost.

In 2014 we created our own research line using Plant Biopharming that uses trichomes, plant-hairs, as natural bio-factories to produce some interesting compounds that may represent an unprecedented opportunity to manufacture affordable high-quality modern medicines and make these available at a global scale.

The project focuses on the use of different plant models, starting with Artemisia annua. Artemisinin, a substance naturally produced in the Artemisia annua plant, is a very powerful and efficacious molecule to treat malaria as showed by the the recent award with the Nobel Prize in Medicine 2015 for its discovery and by the WHO guide-lines to treat malaria.

Additionally, in the near future, artemisinin will be used to treat other important diseases such as cancer, autoimmune & inflammatory diseases, seborrheic dermatitis, schistosomiasis or lyme disease, which affect hundreds of millions of people worldwide every year.

Thanks to our technology and to NEOTEC contribution, we’ll hopefully be able to produce in a natural way an higher quantity of Artemisinin thus increasing significantly plant production yeld.


We're not around right now. But you can send us an email and we'll get back to you, asap.


Log in with your credentials

Forgot your details?